Article

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD Mutations

2020-12-23

Abstract excerpt

The novel betacoranavirus SARS-CoV-2 causes a form of severe pneumonia disease, termed COVID-19 (coronavirus disease 2019). Recombinant human antibodies are proven potent neutralizers of viruses and can block the interaction of viral surface proteins with their host receptors. To develop neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recomb...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2a698d4-b21d-5ec2-8a3f-4b4437cc5bbd
DOI: 10.2139/ssrn.3754550

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD MutationsDOI 10.2139/ssrn.3754550Read

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutationsSemantic proximity Read

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.Semantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity Read

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.Semantic proximity Read

Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of ConcernSemantic proximity Read

A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain coreSemantic proximity Read

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.Semantic proximity Read

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.Semantic proximity Read

Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive VaccinesSemantic proximity Read